Last updated on July 2017

Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

Brief description of study

This study has a randomized, double-blind, placebo-controlled design to assess the efficacy, pharmacodynamics and safety/tolerability of omiganan in patients with mild to moderate atopic dermatitis when applied BID to all atopic dermatitis lesions.

Clinical Study Identifier: NCT03091426

Contact Investigators or Research Sites near you

Start Over

J. (Koos) Burggraaf, MD, PhD

LUMC/Centre for Human Drug Research
Leiden, Netherlands
  Connect »